Clinical trial
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With…
NCT00002866 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00002866 |
|---|---|
| Title | Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer |
| Official title | A Phase I/II Study of Docetaxel and Epirubicin as First-Line Therapy for Metastatic Breast Cancer |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer, Neutropenia |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, docetaxel, epirubicin hydrochloride |
| Enrollment | 50 |
| Start date | Aug 12, 1996 |
| Primary completion | Jul 19, 2005 |
| Completion | Dec 21, 2009 |
| First posted | Apr 27, 2004 |
| Last update posted | Apr 1, 2020 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: